The company showcased its human protein-based delivery platform to the international Duchenne research and patient community.
DNAmic presented its proprietary delivery technology at the International Duchenne Conference organized by Duchenne Parent Project España (DPPE), highlighting recent advances in the development of its human protein-based platform for in vivo gene delivery.
During the meeting, the company shared its vision for overcoming several of the current limitations of existing delivery technologies, including cargo capacity, targeting specificity and the potential for repeated administration.
The conference provided an opportunity to engage with clinicians, researchers, patient organizations and industry leaders working to accelerate the development of new therapies for Duchenne Muscular Dystrophy.
Jesús Beltrán
CSO and CO-Founder DNAmic
DNAmic remains committed to collaborating with the international scientific and patient communities to advance innovative therapies for rare genetic diseases.
DNAmic is a biotechnology company developing a next-generation delivery platform for in vivo gene and cell therapies. Built entirely from engineered human proteins, the company's proprietary bioND™ platform is designed to overcome the key limitations of current viral and non-viral delivery technologies by combining efficient intracellular delivery, programmable cargo encapsulation, and cell-specific targeting within a single modular system.
info@dnamic.bio
